Abstract
The AIDS Malignancy Consortium undertook a pilot trial of valproic acid among patients with AIDS-associated Kaposi sarcoma (KS). Treatment was associated with low toxicity, but the KS clinical response and KS herpesvirus lytic induction rates were not sufficiently high to meet predefined criteria for efficacy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
